研究領(lǐng)域與課題內(nèi)容：

　　一、新藥篩選與應(yīng)用開發(fā)研究

　　1. 特異靶向性抗腫瘤藥物的研究與開發(fā)

　　采用基因工程技術(shù)，將專一性抗腫瘤多肽分子基因進(jìn)行克隆、定點(diǎn)突變，轉(zhuǎn)入蛋白表達(dá)體系進(jìn)行大規(guī)模表達(dá)。研究重組蛋白分子的抗腫瘤特性和機(jī)理，進(jìn)行新藥申報(bào)的相關(guān)體外、體內(nèi)的臨床前新藥研究工作。

　　2. 新型高安全性糖尿病治療藥物的研究

　　從天然降血糖傳統(tǒng)中藥材中克隆、分析降血糖活性成份的基因，進(jìn)行其植物內(nèi)表達(dá)特性、生物學(xué)功能、降血糖藥效的研究。研究比較各不同植物品種中降血糖活性成份的含量變化。分離純化天然降血糖活性成份以及采用基因工程技術(shù)表達(dá)生產(chǎn)重組降血糖活性組分，用于新藥的開發(fā)研究。

　　二、藥物傳送途徑及靶向性分子機(jī)理研究

　　對(duì)外源性生物活性分子體內(nèi)的跨膜運(yùn)輸工具，特別是人源性穿膜肽進(jìn)行其跨膜轉(zhuǎn)運(yùn)機(jī)理、轉(zhuǎn)運(yùn)特性、轉(zhuǎn)運(yùn)靶向性及轉(zhuǎn)運(yùn)后去向等從分子和細(xì)胞水平進(jìn)行理論與應(yīng)用研究。研究、開發(fā)高效及新型穿膜肽，用于藥物的體內(nèi)靶向性運(yùn)輸，提高藥物的安全性和有效性。

　　三、.酶工程：酶的改造、酶的結(jié)構(gòu)與功能，工業(yè)化應(yīng)用研究

　　從多種微生物中篩選、克隆在醫(yī)藥工業(yè)、食品工業(yè)、能源工業(yè)等領(lǐng)域有應(yīng)用前景的各種新型酶類基因，針對(duì)其應(yīng)用進(jìn)行酶的結(jié)構(gòu)性質(zhì)研究與改造，以適用與工業(yè)化應(yīng)用開發(fā)。目前進(jìn)行的相關(guān)酶類有：脂肪酶屬（用于藥物中間體的手性拆分和定向轉(zhuǎn)化），肝素酶屬（用于肝素的生物加工和分析）等。

　　代表性論著：

　　[1] JJ Shangguan, L Fan, X Ju, Q Zhu, FJ Wang, Zhao J*, Xu J-H*. expression and Characterization of a Novel Enantioselecive Lipase from Aspergillus fumigatus. Appl Biochem Biotechnol. 2012;168:1820–1833

　　[2] Wang FJ, Song HL, Wang XM, Zhang WJ, Wang BL, Zhao J*, Hu ZB*. Tandem Multimer expression and Preparation of Hypoglycemic Peptide MC6 from Momordica charantia in Escherichia coli. Appl Biochem Biotechnol. 2012,166:612–619

　　[3] Zhao J*, Gao P, Xiao W, Fan LQ, Wang FJ, Li SX, Liu JW. A novel human derived cell-penetrating peptide in drug delivery. Mol Biol Rep. 2011 38:2649–2656

　　[4] Wang BL, Zhang WJ, Zhao J*, Wang FJ* et al. Gene cloning and expression of a novel hypoglycaemic peptide from Momordica. charantia. J Sci Food Agric. 2011; 91: 2443–2448

　　[5] Shangguan JJ , Liu YQ, Wang FJ, Zhao J*, Fan LQ, Li SX, Xu J-H*. expression and characterization of a novel lipase from Aspergillus fumigatus with high specific activity Appl Biochem Biotechnol. Appl Biochem Biotechnol. 2011;165:949–962

　　[6] Wang Y, Zhao J*, Xu JH*, Fan LQ, Li SX, Zhao LL, Mao XB. Significantly Improved expression and Biochemical Properties of ecombinant Serratia marcescens Lipase as Robust Biocatalyst for  Kinetic Resolution of Chiral Ester. Appl Biochem Biotechnol, 2010 162(8):2387-99.

　　[7] Gao X, Zhao J*,Fan LQ, Li SX, Ma XL, Li L, Ji SL, Yuan QS. expression, purification and characterization of high yield recombinant heparinase III in E. coli. African Journal of Biotechnology (accept)

　　[8] Ye FX, Fan LQ, Xu JH*, Zhao J, He WH, Ni MJ. Construction and expression of Serratia Marcescens ECU1010 Lipase（LipA）in Pichia Pastoris. Journal of Life Science, 2010; 4:9-16

　　[9] Li SX, Wu HZ, Zhao J, Ou L, Zhang* YX. A biochemistry and molecular biology experiment and evaluation system for biotechnology specialty students. Biochemistry and Molecular Biology Education.2010; 38：271-275

　　[10] Chen B, Fan LQ, Xu JH, Zhao J, Zhang X, Ouyang LM.Biocatalytic properties of a recombinant Fusarium proliferatum lactonase with significantly enhanced production by optimal expression in E. coli JM109 (DE3) Appl Biochem Biotechnol. 2010; 162:744-756

　　[11] Fan LQ, Hardy DO, Catterall JF, Zhao J, Li SX. Identification and characterization of an androgen - esponsive Kap promoter enhancer located in the intron II region of human angioten sinogen gene. J Steroid Biochem Mol Biol. 2010;119(3-5):135-40

　　[12] Gao X, Zhao J*, Fan L, Li S, Wang F, Ji S, Yuan Q.. Purification and properties of recombinant GST-heparinase III and optimization of cultivation conditions. Chin J Biotech 2009; 25(11):1718-1724

　　[13] Chen B, Yin HF, Wang ZS, Xu JH*, Fan LQ, Zhao J. Facile synthesis of enantiopure 4-substitued  2-hydroxy-4-butyrolactones using a robust Fusarium lactonase. Advanced Synthesis & Catalysis. 2009; 351: 2959?2966.

　　[14] Zhao LL , Xu JH*, Zhao J , Pan J, Wang ZL. Biochemical properties and potential applications of an organic solvent-tolerant lipase isolated from Serratia marcescens ECU1010. Process Biochemistry. 2008; 43: 626–633

　　[15 ]Fan LQ, Hardy D, Catterall JF，Zhao J, Li SX. Identification and characterization of the minimal androgen-regulated kidney-specific kidney androgen-regulated protein gene promoter. Acta Biochim Biophys Sin. 2008; 40 (12): 979-988

　　[16] Wang G, Zhao J, Liu J, Huang Y, Zhong JJ, Tang W. ,Enhancement of IL-2 and IFN-γexpression and NK cells activity involved in the anti-tumor effect of Ganoderic acid Me in vivo. Int Immunopharmacol. 2007;7(6):864-870.

　　[17] Zhao J, Sun C. Purification and Characterization of b-N-Acetylhexosaminidase from Dolichos lablab，Chinese Journal of Biochemistry and Biophysics. 1994;25(3):171-180

　　[18] 張?jiān)瓶?，高興，汪德健，王富軍，趙健*. 重組谷胱甘肽-S-轉(zhuǎn)移酶-肝素酶I在大腸桿菌中的表達(dá)、純化及其性質(zhì). 華東理工大學(xué)學(xué)報(bào). 2011;37(4): 458-463

　　[19]張文姬，王碧蓮，郭茸愷，王富軍，趙健*. 體外拼裝苦瓜降糖多肽P基因，中國生物制品學(xué)雜志，2011,24(1):94-98

　　[20]華迪，趙健*，范立強(qiáng)，王富軍. 凋亡素融合蛋白在HeLa細(xì)胞中的轉(zhuǎn)導(dǎo)及體外活性分析，華東理工大學(xué)學(xué)報(bào)，2010; 36 (5):651-654

　　[21] 趙健*，肖偉，傅文彬，高鵬，袁勤生，劉建文. 多聚精氨酸蛋白轉(zhuǎn)導(dǎo)域-凋亡素融合蛋白的原核表達(dá)及其生物活性. 中國生物制品學(xué)雜志. 2009;22(5),448-451

　　[20] 趙健*，高鵬，李素霞，袁勤生，劉建文. 凋亡素融合蛋白的基因克隆、表達(dá)與體外活性分析. 華東理工大學(xué)學(xué)報(bào). 2009;35(2),202-206

　　[21]袁勤生等, 趙健(編委). 超氧化物歧化酶. 華東理工大學(xué)出版社. 2009.5

　　[22]胡之壁，王崢濤，趙健(編委) 等. 中藥現(xiàn)代生物技術(shù). 人民衛(wèi)生出版社. 北京2009.9

　　[23]袁勤生, 趙健, 許建和. 現(xiàn)代酶學(xué). 華東理工大學(xué)出版社. 上海. 2007.8

　　[24]袁勤生, 趙健 酶與酶工程（第二版）華東理工大學(xué)出版社. 上海. 2012.8

　　[25]袁勤生, 趙健. 酶與酶工程. 華東理工大學(xué)出版社. 上海. 2006.4